Hylands assists Hejiang Capital to complete the investment of nearly CNY 100 million in a Pharmaceutical Company

Recently, Shenzhen Hejiang Investment Management Co. Ltd. (Hejiang Capital) completed an investment of nearly CNY 100 million in a pharmaceutical company. Hylands Law Firm, as the legal adviser of Hejiang Capital, provided legal services throughout the investment. The project was undertaken by attorney Taosheng LIU, a partner of Hylands’ Shenzhen Office. The members of the project team included Shulian HUANG and Tian ZHOU.

Hejiang Capital is an excellent investment institution focusing on the fields of health and consumption, with representative investment projects such as Chipscreen Biosciences (stock code: 688321), Kangtai Biological (stock code: 300601), Zhilai Sci and Tech (stock code: 300771), Zhou Hei Ya (stock code: HK01458) and HEYTEA.

As one of Hylands Law Firm’s core businesses, the capital markets and securities business has maintained impressive results over the years. Hylands’ Capital Market Team is qualified to engage in the legal business of securities, the relevant legal business of foreign companies involving domestic interests, and the legal business of property rights of state-owned assets. The team has provided legal services for the restructuring, listing, reorganization, and M&A of hundreds of domestic and foreign enterprises, accumulated rich practical experience, and has been highly praised by clients.